Project 1

Project 1

Goal & Research Areas

Our overall objective is to advance to the clinic a novel class of outpatient therapeutics, termed programmable antivirals, that target highly-conserved RNA structures in the genome of SARS-CoV-2 and other respiratory viruses of pandemic concern.

Core Leader & Team

Jeffrey Glenn

Jeffrey Glenn

Learn More Learn More
Menashe Elazar

Menashe Elazar

Learn More Learn More
Edward Pham

Edward Pham

Learn More Learn More
Rhiju Das

Rhiju Das

Learn More Learn More
Wah Chiu

Wah Chiu

Learn More Learn More
Matt Disney

Matt Disney

Learn More Learn More
Chien-Te (Kent) Tseng, PhD

Chien-Te Kent Tseng

Learn More Learn More

Hot Topic

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...

Read More Learn More
Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.

Read More Learn More
Antiviral Program for Pandemics

Antiviral Program for Pandemics

The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.

Read More Learn More
Jeffrey Glenn
Jeffrey Glenn MD/PhD, U.C.S.F Joseph D Grant Professor of Medicine/Microbiology and Immunology;

Dr. Jeffrey Glenn is a Professor of Medicine, Microbiology & Immunology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He is the founder of Eiger Biopharmaceuticals who is developing Lambda for hepatitis delta and COVID.

Dr. Glenn is an author on over 100 scientific articles and book chapters, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. He is the principal investigator on multiple NIH grants, and a member of FDA Antiviral Drugs.

He is an international authority on developing novel antiviral therapeutics.